The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging o...
Gespeichert in:
| Veröffentlicht in: | ESMO OPEN 2023-06, Vol.8 (3), p.101567, Article 101567 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 101567 |
| container_title | ESMO OPEN |
| container_volume | 8 |
| creator | Ducreux, M. Abou-Alfa, G.K. Bekaii-Saab, T. Berlin, J. Cervantes, A. de Baere, T. Eng, C. Galle, P. Gill, S. Gruenberger, T. Haustermans, K. Lamarca, A. Laurent-Puig, P. Llovet, J.M. Lordick, F. Macarulla, T. Mukherji, D. Muro, K. Obermannova, R. O’Connor, J.-M. O’Reilly, E.M. Osterlund, P. Philip, P. Prager, G. Ruiz-Garcia, E. Sangro, B. Seufferlein, T. Tabernero, J. Verslype, C. Wasan, H. Van Cutsem, E. |
| description | This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
•The incidence of HCC will continue to rise.•HCC is curable at an early stage.•New locoregional treatments such as radioembolisation are showing impressive results.•A combination of immunotherapy is the gold standard of first-line treatment for advanced hepatocellular cancer.•There are more and more active systemic treatment options. |
| doi_str_mv | 10.1016/j.esmoop.2023.101567 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_680896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2059702923007986</els_id><sourcerecordid>2822378159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-81fabdca9a477392c92e077c3b4bb524b9ad17f7cb7fc961639f745f97a1d1883</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqX_ACEfOXS3tvPh-AKCVSlIRT1QxNGa2JNdL4kd7GSB_8SPxFGWqr1wsvXmzXv2zMuyl4yuGWXV5X6Nsfd-WHPK8xkqK_EkO-W0lCtBuXz64H6Snce4p5QyUSSwep6d5IJXOa3ZafbnboekBwdb7NGNxLdkhwOMXmPXTR0EoiFo63wPa7KZQphJ-GvAkLiDddY7As6QgNr3ScHAmKBIDAZ7QEPa4HsyJg9ejDty9eXz7eU3HzpDNt5tA8ZIksA1xDF460aMo3XQkQ04jeGCvE_e2HkHFyR9lL_InrXQRTw_nmfZ1w9Xd5uPq5vb60-bdzcrXVI-rmrWQmM0SCiEyCXXkiMVQudN0TQlLxoJholW6Ea0WlasymUrirKVAphhdZ2fZatFN_7EYWrUEGwP4bfyYNUR-p5uqKqa1rJK_LcLP1V6NDrNKED3qO1xxdmd2vqDYpQXJWMsKbw-KgT_Y0pjUL2N8wrAoZ-i4jXnuahZKRO1WKg6-BgDtvc-jKo5HGqvlnCoORxqCUdqe_XwjfdN_6KQCG8WAqbJHiwGFbXFtAdj03JHZbz9v8NfhRHQ6Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2822378159</pqid></control><display><type>article</type><title>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><creator>Ducreux, M. ; Abou-Alfa, G.K. ; Bekaii-Saab, T. ; Berlin, J. ; Cervantes, A. ; de Baere, T. ; Eng, C. ; Galle, P. ; Gill, S. ; Gruenberger, T. ; Haustermans, K. ; Lamarca, A. ; Laurent-Puig, P. ; Llovet, J.M. ; Lordick, F. ; Macarulla, T. ; Mukherji, D. ; Muro, K. ; Obermannova, R. ; O’Connor, J.-M. ; O’Reilly, E.M. ; Osterlund, P. ; Philip, P. ; Prager, G. ; Ruiz-Garcia, E. ; Sangro, B. ; Seufferlein, T. ; Tabernero, J. ; Verslype, C. ; Wasan, H. ; Van Cutsem, E.</creator><creatorcontrib>Ducreux, M. ; Abou-Alfa, G.K. ; Bekaii-Saab, T. ; Berlin, J. ; Cervantes, A. ; de Baere, T. ; Eng, C. ; Galle, P. ; Gill, S. ; Gruenberger, T. ; Haustermans, K. ; Lamarca, A. ; Laurent-Puig, P. ; Llovet, J.M. ; Lordick, F. ; Macarulla, T. ; Mukherji, D. ; Muro, K. ; Obermannova, R. ; O’Connor, J.-M. ; O’Reilly, E.M. ; Osterlund, P. ; Philip, P. ; Prager, G. ; Ruiz-Garcia, E. ; Sangro, B. ; Seufferlein, T. ; Tabernero, J. ; Verslype, C. ; Wasan, H. ; Van Cutsem, E.</creatorcontrib><description>This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
•The incidence of HCC will continue to rise.•HCC is curable at an early stage.•New locoregional treatments such as radioembolisation are showing impressive results.•A combination of immunotherapy is the gold standard of first-line treatment for advanced hepatocellular cancer.•There are more and more active systemic treatment options.</description><identifier>ISSN: 2059-7029</identifier><identifier>EISSN: 2059-7029</identifier><identifier>DOI: 10.1016/j.esmoop.2023.101567</identifier><identifier>PMID: 37263081</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - therapy ; chemoembolisation ; Gastrointestinal Neoplasms - diagnosis ; Gastrointestinal Neoplasms - therapy ; hepatocellular carcinoma ; Humans ; immunotherapy ; Liver Neoplasms - diagnosis ; Liver Neoplasms - therapy ; liver transplantation ; Practice Guidelines as Topic ; radioembolisation ; Review</subject><ispartof>ESMO OPEN, 2023-06, Vol.8 (3), p.101567, Article 101567</ispartof><rights>2023 The Author(s)</rights><rights>Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>2023 The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-81fabdca9a477392c92e077c3b4bb524b9ad17f7cb7fc961639f745f97a1d1883</citedby><cites>FETCH-LOGICAL-c502t-81fabdca9a477392c92e077c3b4bb524b9ad17f7cb7fc961639f745f97a1d1883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245111/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245111/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37263081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:153604056$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Ducreux, M.</creatorcontrib><creatorcontrib>Abou-Alfa, G.K.</creatorcontrib><creatorcontrib>Bekaii-Saab, T.</creatorcontrib><creatorcontrib>Berlin, J.</creatorcontrib><creatorcontrib>Cervantes, A.</creatorcontrib><creatorcontrib>de Baere, T.</creatorcontrib><creatorcontrib>Eng, C.</creatorcontrib><creatorcontrib>Galle, P.</creatorcontrib><creatorcontrib>Gill, S.</creatorcontrib><creatorcontrib>Gruenberger, T.</creatorcontrib><creatorcontrib>Haustermans, K.</creatorcontrib><creatorcontrib>Lamarca, A.</creatorcontrib><creatorcontrib>Laurent-Puig, P.</creatorcontrib><creatorcontrib>Llovet, J.M.</creatorcontrib><creatorcontrib>Lordick, F.</creatorcontrib><creatorcontrib>Macarulla, T.</creatorcontrib><creatorcontrib>Mukherji, D.</creatorcontrib><creatorcontrib>Muro, K.</creatorcontrib><creatorcontrib>Obermannova, R.</creatorcontrib><creatorcontrib>O’Connor, J.-M.</creatorcontrib><creatorcontrib>O’Reilly, E.M.</creatorcontrib><creatorcontrib>Osterlund, P.</creatorcontrib><creatorcontrib>Philip, P.</creatorcontrib><creatorcontrib>Prager, G.</creatorcontrib><creatorcontrib>Ruiz-Garcia, E.</creatorcontrib><creatorcontrib>Sangro, B.</creatorcontrib><creatorcontrib>Seufferlein, T.</creatorcontrib><creatorcontrib>Tabernero, J.</creatorcontrib><creatorcontrib>Verslype, C.</creatorcontrib><creatorcontrib>Wasan, H.</creatorcontrib><creatorcontrib>Van Cutsem, E.</creatorcontrib><title>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022</title><title>ESMO OPEN</title><addtitle>ESMO Open</addtitle><description>This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
•The incidence of HCC will continue to rise.•HCC is curable at an early stage.•New locoregional treatments such as radioembolisation are showing impressive results.•A combination of immunotherapy is the gold standard of first-line treatment for advanced hepatocellular cancer.•There are more and more active systemic treatment options.</description><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>chemoembolisation</subject><subject>Gastrointestinal Neoplasms - diagnosis</subject><subject>Gastrointestinal Neoplasms - therapy</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>immunotherapy</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - therapy</subject><subject>liver transplantation</subject><subject>Practice Guidelines as Topic</subject><subject>radioembolisation</subject><subject>Review</subject><issn>2059-7029</issn><issn>2059-7029</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9Uk1v1DAQjRCIVqX_ACEfOXS3tvPh-AKCVSlIRT1QxNGa2JNdL4kd7GSB_8SPxFGWqr1wsvXmzXv2zMuyl4yuGWXV5X6Nsfd-WHPK8xkqK_EkO-W0lCtBuXz64H6Snce4p5QyUSSwep6d5IJXOa3ZafbnboekBwdb7NGNxLdkhwOMXmPXTR0EoiFo63wPa7KZQphJ-GvAkLiDddY7As6QgNr3ScHAmKBIDAZ7QEPa4HsyJg9ejDty9eXz7eU3HzpDNt5tA8ZIksA1xDF460aMo3XQkQ04jeGCvE_e2HkHFyR9lL_InrXQRTw_nmfZ1w9Xd5uPq5vb60-bdzcrXVI-rmrWQmM0SCiEyCXXkiMVQudN0TQlLxoJholW6Ea0WlasymUrirKVAphhdZ2fZatFN_7EYWrUEGwP4bfyYNUR-p5uqKqa1rJK_LcLP1V6NDrNKED3qO1xxdmd2vqDYpQXJWMsKbw-KgT_Y0pjUL2N8wrAoZ-i4jXnuahZKRO1WKg6-BgDtvc-jKo5HGqvlnCoORxqCUdqe_XwjfdN_6KQCG8WAqbJHiwGFbXFtAdj03JHZbz9v8NfhRHQ6Q</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Ducreux, M.</creator><creator>Abou-Alfa, G.K.</creator><creator>Bekaii-Saab, T.</creator><creator>Berlin, J.</creator><creator>Cervantes, A.</creator><creator>de Baere, T.</creator><creator>Eng, C.</creator><creator>Galle, P.</creator><creator>Gill, S.</creator><creator>Gruenberger, T.</creator><creator>Haustermans, K.</creator><creator>Lamarca, A.</creator><creator>Laurent-Puig, P.</creator><creator>Llovet, J.M.</creator><creator>Lordick, F.</creator><creator>Macarulla, T.</creator><creator>Mukherji, D.</creator><creator>Muro, K.</creator><creator>Obermannova, R.</creator><creator>O’Connor, J.-M.</creator><creator>O’Reilly, E.M.</creator><creator>Osterlund, P.</creator><creator>Philip, P.</creator><creator>Prager, G.</creator><creator>Ruiz-Garcia, E.</creator><creator>Sangro, B.</creator><creator>Seufferlein, T.</creator><creator>Tabernero, J.</creator><creator>Verslype, C.</creator><creator>Wasan, H.</creator><creator>Van Cutsem, E.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20230601</creationdate><title>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022</title><author>Ducreux, M. ; Abou-Alfa, G.K. ; Bekaii-Saab, T. ; Berlin, J. ; Cervantes, A. ; de Baere, T. ; Eng, C. ; Galle, P. ; Gill, S. ; Gruenberger, T. ; Haustermans, K. ; Lamarca, A. ; Laurent-Puig, P. ; Llovet, J.M. ; Lordick, F. ; Macarulla, T. ; Mukherji, D. ; Muro, K. ; Obermannova, R. ; O’Connor, J.-M. ; O’Reilly, E.M. ; Osterlund, P. ; Philip, P. ; Prager, G. ; Ruiz-Garcia, E. ; Sangro, B. ; Seufferlein, T. ; Tabernero, J. ; Verslype, C. ; Wasan, H. ; Van Cutsem, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-81fabdca9a477392c92e077c3b4bb524b9ad17f7cb7fc961639f745f97a1d1883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>chemoembolisation</topic><topic>Gastrointestinal Neoplasms - diagnosis</topic><topic>Gastrointestinal Neoplasms - therapy</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>immunotherapy</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - therapy</topic><topic>liver transplantation</topic><topic>Practice Guidelines as Topic</topic><topic>radioembolisation</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ducreux, M.</creatorcontrib><creatorcontrib>Abou-Alfa, G.K.</creatorcontrib><creatorcontrib>Bekaii-Saab, T.</creatorcontrib><creatorcontrib>Berlin, J.</creatorcontrib><creatorcontrib>Cervantes, A.</creatorcontrib><creatorcontrib>de Baere, T.</creatorcontrib><creatorcontrib>Eng, C.</creatorcontrib><creatorcontrib>Galle, P.</creatorcontrib><creatorcontrib>Gill, S.</creatorcontrib><creatorcontrib>Gruenberger, T.</creatorcontrib><creatorcontrib>Haustermans, K.</creatorcontrib><creatorcontrib>Lamarca, A.</creatorcontrib><creatorcontrib>Laurent-Puig, P.</creatorcontrib><creatorcontrib>Llovet, J.M.</creatorcontrib><creatorcontrib>Lordick, F.</creatorcontrib><creatorcontrib>Macarulla, T.</creatorcontrib><creatorcontrib>Mukherji, D.</creatorcontrib><creatorcontrib>Muro, K.</creatorcontrib><creatorcontrib>Obermannova, R.</creatorcontrib><creatorcontrib>O’Connor, J.-M.</creatorcontrib><creatorcontrib>O’Reilly, E.M.</creatorcontrib><creatorcontrib>Osterlund, P.</creatorcontrib><creatorcontrib>Philip, P.</creatorcontrib><creatorcontrib>Prager, G.</creatorcontrib><creatorcontrib>Ruiz-Garcia, E.</creatorcontrib><creatorcontrib>Sangro, B.</creatorcontrib><creatorcontrib>Seufferlein, T.</creatorcontrib><creatorcontrib>Tabernero, J.</creatorcontrib><creatorcontrib>Verslype, C.</creatorcontrib><creatorcontrib>Wasan, H.</creatorcontrib><creatorcontrib>Van Cutsem, E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>ESMO OPEN</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ducreux, M.</au><au>Abou-Alfa, G.K.</au><au>Bekaii-Saab, T.</au><au>Berlin, J.</au><au>Cervantes, A.</au><au>de Baere, T.</au><au>Eng, C.</au><au>Galle, P.</au><au>Gill, S.</au><au>Gruenberger, T.</au><au>Haustermans, K.</au><au>Lamarca, A.</au><au>Laurent-Puig, P.</au><au>Llovet, J.M.</au><au>Lordick, F.</au><au>Macarulla, T.</au><au>Mukherji, D.</au><au>Muro, K.</au><au>Obermannova, R.</au><au>O’Connor, J.-M.</au><au>O’Reilly, E.M.</au><au>Osterlund, P.</au><au>Philip, P.</au><au>Prager, G.</au><au>Ruiz-Garcia, E.</au><au>Sangro, B.</au><au>Seufferlein, T.</au><au>Tabernero, J.</au><au>Verslype, C.</au><au>Wasan, H.</au><au>Van Cutsem, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022</atitle><jtitle>ESMO OPEN</jtitle><addtitle>ESMO Open</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>8</volume><issue>3</issue><spage>101567</spage><pages>101567-</pages><artnum>101567</artnum><issn>2059-7029</issn><eissn>2059-7029</eissn><abstract>This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
•The incidence of HCC will continue to rise.•HCC is curable at an early stage.•New locoregional treatments such as radioembolisation are showing impressive results.•A combination of immunotherapy is the gold standard of first-line treatment for advanced hepatocellular cancer.•There are more and more active systemic treatment options.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37263081</pmid><doi>10.1016/j.esmoop.2023.101567</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2059-7029 |
| ispartof | ESMO OPEN, 2023-06, Vol.8 (3), p.101567, Article 101567 |
| issn | 2059-7029 2059-7029 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_680896 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online |
| subjects | Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - therapy chemoembolisation Gastrointestinal Neoplasms - diagnosis Gastrointestinal Neoplasms - therapy hepatocellular carcinoma Humans immunotherapy Liver Neoplasms - diagnosis Liver Neoplasms - therapy liver transplantation Practice Guidelines as Topic radioembolisation Review |
| title | The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T01%3A48%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20management%20of%20hepatocellular%20carcinoma.%20Current%20expert%20opinion%20and%20recommendations%20derived%20from%20the%2024th%20ESMO/World%20Congress%20on%20Gastrointestinal%20Cancer,%20Barcelona,%202022&rft.jtitle=ESMO%20OPEN&rft.au=Ducreux,%20M.&rft.date=2023-06-01&rft.volume=8&rft.issue=3&rft.spage=101567&rft.pages=101567-&rft.artnum=101567&rft.issn=2059-7029&rft.eissn=2059-7029&rft_id=info:doi/10.1016/j.esmoop.2023.101567&rft_dat=%3Cproquest_swepu%3E2822378159%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2822378159&rft_id=info:pmid/37263081&rft_els_id=S2059702923007986&rfr_iscdi=true |